Dynasty Wealth Management LLC Sells 18,791 Shares of Astrazeneca Plc $AZN

by · The Markets Daily

Dynasty Wealth Management LLC reduced its stake in Astrazeneca Plc (NYSE:AZN – Free Report) by 44.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,782 shares of the company’s stock after selling 18,791 shares during the quarter. Dynasty Wealth Management LLC’s holdings in Astrazeneca were worth $4,373,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Lloyd Advisory Services LLC. bought a new stake in shares of Astrazeneca in the 4th quarter worth approximately $35,000. Basepoint Wealth LLC purchased a new position in Astrazeneca in the 4th quarter worth approximately $44,000. Bangor Savings Bank raised its holdings in Astrazeneca by 102.7% in the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after acquiring an additional 154 shares during the last quarter. Eagle Bay Advisors LLC purchased a new position in Astrazeneca in the 4th quarter worth approximately $30,000. Finally, Triumph Capital Management purchased a new position in Astrazeneca in the 3rd quarter worth approximately $25,000. 20.35% of the stock is owned by institutional investors.

Astrazeneca Price Performance

Shares of AZN opened at $177.34 on Wednesday. The firm has a market cap of $275.04 billion, a PE ratio of 26.63, a P/E/G ratio of 1.43 and a beta of 0.25. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The firm has a fifty day simple moving average of $191.20 and a two-hundred day simple moving average of $184.28. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71.

Astrazeneca (NYSE:AZN – Get Free Report) last announced its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. On average, equities analysts anticipate that Astrazeneca Plc will post 10.26 EPS for the current year.

Analysts Set New Price Targets

AZN has been the subject of a number of recent analyst reports. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, May 13th. Weiss Ratings initiated coverage on shares of Astrazeneca in a report on Wednesday, March 11th. They issued a “buy (b)” rating for the company. UBS Group restated a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a report on Thursday, May 21st. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a report on Monday. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $205.33.

View Our Latest Stock Analysis on Astrazeneca

Astrazeneca Company Profile

(Free Report)

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

Read More